Aysun A.
- Country
- The Netherlands
- Department
- Epilepsy
Research Overview
- Efficacy of Add-On Cannabidiol and Dronabinol in Pediatric Refractory Epilepsy: A Randomized, Double-Blind, Placebo-Controlled Trial
- Efficacy and Safety of Bexicaserin in Seizure Management for Pediatric and Adult Dravet Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety of Bexicaserin Hydrochloride in Developmental and Epileptic Encephalopathies: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 43 of 53 partner sites.
Specializations
Epilepsy and Focal Seizure Disorders
Aysun Altinbas is involved in clinical research focused on epilepsy with an emphasis on focal (partial onset) epilepsy, refractory epilepsy, and refractory focal onset epilepsy. The trial portfolio also includes adjunctive treatment strategies for seizure control in people with persistent seizure burden.
- Focal seizures
- Refractory epilepsy
- Adjunctive antiseizure therapy
Her site-based activity is connected to research at Stichting Epilepsy Instellingen Nederland and Epilepsie Instellingen Nederland Stichting in Zwolle.
Developmental and Epileptic Encephalopathies
Her research interests extend to severe early-onset epileptic syndromes, including developmental and epileptic encephalopathies, Dravet syndrome, Lennox-Gastaut syndrome, and CDKL5 deficiency disorder. This area reflects involvement in therapies aimed at reducing countable motor seizures in complex neurodevelopmental epilepsy syndromes.
- Dravet syndrome
- Lennox-Gastaut syndrome
- CDKL5 deficiency disorder
Her clinical trial landscape also includes broader DEE populations and related rare epileptic syndromes.
Rare Epileptic Syndromes and Seizure Innovation
She is engaged in studies addressing rare and treatment-resistant seizure disorders, including Dravet and Lennox-Gastaut syndromes and other severe epileptic encephalopathies. The therapeutic focus includes novel approaches for seizure reduction and long-term tolerability in pediatric and adult populations.
- Severe rare seizure disorders
- Countable motor seizures
- Long-term safety and tolerability
These research activities place emphasis on innovative antiepileptic treatment options for difficult-to-control syndromes.
Narcolepsy and Idiopathic Hypersomnia
Aysun Altinbas also contributes to research in central disorders of hypersomnolence, particularly narcolepsy type 1, narcolepsy type 2, narcolepsy with cataplexy, and idiopathic hypersomnia. The therapeutic interest centers on improving excessive daytime sleepiness and related symptoms.
- Excessive daytime sleepiness
- Narcolepsy type 1
- Idiopathic hypersomnia
Her involvement spans both narcolepsy and hypersomnia populations, reflecting a focused interest in sleep-wake disorder treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.